Shalvata Mental Health Center — CureCurrent

Published trials34

Recruiting shown1

Roles2

SourceClinicalTrials.gov

Clinical trials

34 shown

Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections: Translating Epidemiology to Deep-phenotyping.NCT07453420 · lead sponsor · 2024-08-17

ACTIVE_NOT_RECRUITING

Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental IllnessNCT04551027 · lead sponsor · 2020-09-01

Using Clinical Process Indicators, Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) to Improve the Quality and Continuity of Care for Psychiatric PatientsNCT04314154 · lead sponsor · 2020-04-15

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental IllnessNCT03566069 · lead sponsor · 2018-06-01

Evaluation of the H1-Coil TMS- Double Blind Placebo Controlled Study in Adolescent Patients Suffering From Major DepressionNCT03541707 · lead sponsor · 2018-05-01

The Experience of Older Adults Facing Depression for the First Time in Old AgeNCT03009448 · lead sponsor · 2017-03-01

Intra-nasal vs. Intra-venous Ketamine AdministrationNCT02644629 · lead sponsor · 2016-04-01

Open-Label Placebo for the Treatment of DepressionNCT02666989 · lead sponsor · 2016-02-01

The Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in SchizophreniaNCT02588014 · lead sponsor · 2015-11-01

Neuromarkers Identification in Major Depressive Disorder Based on Monitoring MeasuresNCT02222012 · lead sponsor · 2014-08-01

Routine Outcome Monitoring in Mental Health OutpatientNCT02095457 · lead sponsor · 2014-07-01

Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic PatientsNCT01729572 · lead sponsor · 2014-01-01

Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol LevelsNCT01754532 · lead sponsor · 2013-01-01

Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD PatientsNCT01311570 · lead sponsor · 2012-10-01

A Prospective, Comparative Study to Explore the Efficacy and Safety of the Five Channels Multiway Deep Transcranial Magnetic Stimulation (TMS) Device in Subjects With Major Depression Disorder (MDD)NCT01501825 · lead sponsor · 2012-08-01

Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar DepressionNCT01574742 · lead sponsor · 2012-06-01

Body Movement Imitation and Perspective Perception Among Psychiatric PatientsNCT01375894 · lead sponsor · 2012-03-01

Evaluation of the H-Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for Treatment of Major Depressive Episode in the ElderlyNCT01521052 · lead sponsor · 2012-01-01

Chronic Cannabis Users: A Model for Negative Symptoms in SchizophreniaNCT01382433 · lead sponsor · 2011-07-01

A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective DisorderNCT01389908 · lead sponsor · 2011-06-01

Magnetoencephalographic (MEG) Evidence for Novel Metaphor Processing Among Schizophrenic PatientsNCT01325363 · lead sponsor · 2011-04-01

Evaluation of Generalization Paradigm Patterns Among Different Psychiatric DisordersNCT01501812 · lead sponsor · 2011-03-01

Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled StudyNCT01133080 · lead sponsor · 2010-06-01

Magnetoencephalographic (MEG) Correlates of Negative Symptoms in Patients Suffering From Schizophrenia and Their Influence by Add-on TreatmentsNCT00894296 · lead sponsor · 2009-03-01

Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic TreatmentNCT00789022 · lead sponsor · 2009-01-01

Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive EpisodeNCT00807105 · lead sponsor · 2008-06-01

Tolerability, Safety and Efficacy of the H1-coil Deep Transcranial Magnetic Stimulation in Subjects With Negative Symptoms and Cognitive Deficits of SchizophreniaNCT00685321 · lead sponsor · 2008-06-01

The Effect of Intranasal Administration of Oxytocin on Empathic Abilities.NCT00813436 · lead sponsor · 2008-05-01

Emotional and Cognitive Abilites of Schizophrenia Patients at Various Time PointsNCT00518999 · lead sponsor · 2007-08-01

Evaluation of the H1-coil Deep TMS in the Treatment of Negative Symptoms and Cognitive Deficit in SchizophreniaNCT00445926 · lead sponsor · 2006-07-01

Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major DepressionNCT00445237 · lead sponsor · 2006-05-01

Minocycline for the Treatment of Early-Phase SchizophreniaNCT00733057 · lead sponsor · 2003-08-01

Stratification and Treatment in Early Psychosis Study - ENHANCENCT06778564 · collaborator · 2026-09-01

Stratification and Treatment in Early Psychosis Study -ASSISTNCT07326124 · collaborator · 2026-06-01

NOT_YET_RECRUITING

Sponsor roles

lead sponsor32

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.